IL276788A - Compounds with activity that causes iron-dependent cell death and methods of using them - Google Patents

Compounds with activity that causes iron-dependent cell death and methods of using them

Info

Publication number
IL276788A
IL276788A IL276788A IL27678820A IL276788A IL 276788 A IL276788 A IL 276788A IL 276788 A IL276788 A IL 276788A IL 27678820 A IL27678820 A IL 27678820A IL 276788 A IL276788 A IL 276788A
Authority
IL
Israel
Prior art keywords
compounds
methods
inducing activity
ferroptosis
ferroptosis inducing
Prior art date
Application number
IL276788A
Other languages
English (en)
Hebrew (he)
Original Assignee
Ferro Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferro Therapeutics Inc filed Critical Ferro Therapeutics Inc
Publication of IL276788A publication Critical patent/IL276788A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL276788A 2018-02-28 2020-08-18 Compounds with activity that causes iron-dependent cell death and methods of using them IL276788A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636614P 2018-02-28 2018-02-28
PCT/US2019/019854 WO2019168999A1 (fr) 2018-02-28 2019-02-27 Composés ayant une activité inductrice de la ferroptose et procédés de leur utilisation

Publications (1)

Publication Number Publication Date
IL276788A true IL276788A (en) 2020-10-29

Family

ID=65729467

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276788A IL276788A (en) 2018-02-28 2020-08-18 Compounds with activity that causes iron-dependent cell death and methods of using them

Country Status (15)

Country Link
US (2) US11098040B2 (fr)
EP (1) EP3759075A1 (fr)
JP (1) JP7348906B2 (fr)
KR (1) KR20200135961A (fr)
CN (1) CN112041301A (fr)
AR (2) AR114417A1 (fr)
AU (1) AU2019229256A1 (fr)
BR (1) BR112020017561A2 (fr)
CA (1) CA3092143A1 (fr)
EA (1) EA202091846A1 (fr)
IL (1) IL276788A (fr)
MX (2) MX2020008906A (fr)
SG (1) SG11202008230PA (fr)
TW (1) TW202000663A (fr)
WO (1) WO2019168999A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
AU2020228056A1 (en) * 2019-02-27 2021-09-16 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use
CN110511253B (zh) * 2019-09-04 2023-10-13 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法
CN110627786B (zh) * 2019-10-29 2020-11-24 株洲千金药业股份有限公司 一种他达拉非中间体的制备方法
EP4076434A1 (fr) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Polythérapies anticancéreuses ayant des inducteurs de désassemblage cellulaire dépendant du fer
US11998534B2 (en) * 2020-02-12 2024-06-04 Eubulus Biotherapeutics Inc. GPX4 inhibitor in combination with anticancer agent for treating proliferative disease
CN115243719A (zh) * 2020-03-06 2022-10-25 北京先通生物医药技术有限公司 CTB006与Ponatinib联合应用
TW202227399A (zh) * 2020-08-26 2022-07-16 美商費洛醫療公司 化合物及使用方法
WO2022216066A1 (fr) * 2021-04-08 2022-10-13 서울대학교산학협력단 Biomarqueur pour l'estimation du pronostic chez des patients atteints de cancer et son utilisation
CN113336748B (zh) * 2021-04-12 2022-03-25 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024015637A1 (fr) * 2022-07-15 2024-01-18 Ferro Therapeutics, Inc. Inhibiteurs de la glutathion peroxydase 4 (gpx4) pour le traitement du cancer
WO2024039860A1 (fr) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. Dérivés de 2,3,4,9-tétrahydro-1h-pyrido[3,4-b]indole en tant que modulateurs du récepteur des oestrogènes pour le traitement du cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
WO2001094345A2 (fr) 2000-06-07 2001-12-13 Lilly Icos Llc Composes chimiques
US20030153575A1 (en) * 2000-06-08 2003-08-14 Orme Mark W. Tetracyclic diketopiperazine compounds as pdev inhibitors
ATE297926T1 (de) * 2000-10-02 2005-07-15 Lilly Icos Llc Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
US6960587B2 (en) 2000-11-08 2005-11-01 Lilly Icos Llc Condensed pyrazindione derivatives as PDE inhibitors
EP2324886A1 (fr) * 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Nouveaux analogues deutériés de tadalafil
EP1914235A1 (fr) * 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Dérivés chirales tetra-hydro beta-carbolines en tant qu'agents antiparasitaires
WO2008103470A2 (fr) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Composés létaux dépendants du signal de ras oncogénique
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
US9169247B2 (en) * 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
US9695133B2 (en) * 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
WO2015051149A1 (fr) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Analogues de sorafenib et leurs utilisations
EP3094332B1 (fr) 2014-01-15 2018-09-12 The Trustees of Columbia University in the City of New York Analogues carbonylés de l'érastine et leur utilisation
EP3233070A4 (fr) 2014-12-16 2018-08-08 ADT Pharmaceuticals, LLC Composés d'acétamide indényle inhibiteur de ras, compositions et utilisations
CN108377643B (zh) 2015-05-29 2021-09-21 纪念斯隆凯特琳癌症中心 使用超小纳米粒子通过铁死亡诱导营养素剥夺癌细胞的细胞死亡的治疗方法
KR102099159B1 (ko) 2015-11-12 2020-04-10 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
WO2017120445A1 (fr) 2016-01-07 2017-07-13 The Broad Institute, Inc. Composés et des méthodes pour augmenter l'infiltration tumorale par des cellules immunitaires
AR107314A1 (es) 2016-01-08 2018-04-18 Ecolab Usa Inc Modificadores de la reología del petróleo pesado para la mejora del flujo durante las operaciones de producción y transporte
EP3411034B1 (fr) 2016-02-05 2020-11-25 Inventisbio Inc. Agents de dégradation sélectifs des récepteurs des strogènes et leurs utilisations
WO2018118711A1 (fr) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Inducteurs de ferroptose à petites molécules
WO2018218087A1 (fr) 2017-05-24 2018-11-29 K-Gen, Inc. Méthodes de traitement du cancer
EP4085919A3 (fr) 2017-07-21 2023-02-08 Novartis AG Compositions et procédés permettant de traiter un cancer
WO2019106434A1 (fr) 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Dérivés aromatiques hétérocycliques pour le traitement de troubles liés à la ferroptose
US20200383943A1 (en) 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
CN109796424A (zh) 2019-02-19 2019-05-24 四川大学 一种抑制铁死亡的小分子化合物及其制备方法与应用
AU2020228056A1 (en) 2019-02-27 2021-09-16 Ferro Therapeutics, Inc. Compounds with ferroptosis inducing activity and methods of their use

Also Published As

Publication number Publication date
US20190263802A1 (en) 2019-08-29
AR118205A1 (es) 2021-09-22
MX2020008906A (es) 2021-02-26
SG11202008230PA (en) 2020-09-29
AR114417A1 (es) 2020-09-02
EA202091846A1 (ru) 2021-06-01
US20230039846A1 (en) 2023-02-09
JP2021515010A (ja) 2021-06-17
BR112020017561A2 (pt) 2020-12-22
JP7348906B2 (ja) 2023-09-21
KR20200135961A (ko) 2020-12-04
TW202000663A (zh) 2020-01-01
AU2019229256A1 (en) 2020-09-17
EP3759075A1 (fr) 2021-01-06
US11098040B2 (en) 2021-08-24
CN112041301A (zh) 2020-12-04
MX2023001527A (es) 2023-03-06
WO2019168999A1 (fr) 2019-09-06
CA3092143A1 (fr) 2019-09-06

Similar Documents

Publication Publication Date Title
IL276788A (en) Compounds with activity that causes iron-dependent cell death and methods of using them
IL290809A (en) Tau-protein targeted protacs and related methods of use
IL292094A (en) Neoantigens and methods for using them
IL285730A (en) Compounds with proptosis-inducing activity and methods of using them
IL273918A (en) Trispecific proteins and methods of use
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL292810A (en) Therapeutic compounds and methods of use
IL277963A (en) Bicyclic carboxamides and methods of using them
IL276687A (en) Trialkyne coupling agents and methods of using them
IL265955A (en) Therapeutic compounds and methods of use thereof
HK1252567A1 (zh) 被取代的苯甲酰胺和其使用方法
ZA202005674B (en) Glucoamylases and methods of use thereof
IL289748A (en) Heterodimers and methods of using them
IL283782A (en) Analosomes and methods of use
IL287966A (en) Automatic injector and associated methods of use
GB201715194D0 (en) Compounds and their therapeutic use
IL291180A (en) Bee vaccines and methods of use
HK1258056A1 (zh) 治療性化合物和其使用方法
IL276792A (en) Inhaler and methods for using it
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
GB2589398B (en) Compounds and methods of use
GB201900741D0 (en) Liver-specifc inducible prometers and methods of use thereof
GB201709186D0 (en) Construction block and methods of use